Eliquis, a blood thinner marketed in partnership with Bristol Myers Squibb, is Pfizer's largest revenue stream at the moment. It could begin competing with generic versions in the U.S. market in 2028, but the gap it leaves won't be too difficult to fill. Eliquis is responsible for only about 10.3% of Pfizer's total revenue stream.

Worried about the next round of tariffs? Tech disruption from DeepSeek? The geopolitical landscape? Then these low-beta dividend stocks could be the answer.

In recent years, investors have increasingly shifted away from UK equities, favoring global stocks, particularly high-growth sectors like US technology.

Some companies really treat their investors well. They pay lucrative dividends that they routinely raise. That makes them excellent stocks to buy and hold for passive income. Several high-yielding dividend stocks recently raised their payouts again.

The annualized dividend paid by AbbVie is $6.56/share, currently paid in quarterly installments, and its most recent dividend ex-date was on 01/15/2025

We recently compiled a list of the 12 Best 5% Dividend Stocks To Buy According To Hedge Funds. In this article, we are going to take a look at where Edison International (NYSE:EIX) stands against

AbbVie is a Dividend King that's quickly moving past reliance on Humira. Enbridge shouldn't be affected by potential Canadian tariffs and has increased its dividend for 30 consecutive years. Pfizer is poised for growth despite facing a patent cliff,